

CY 2024 Real World Testing Report for NewCropRx

Executive Summary

This is the test report for CY 2024 real world testing for our NewCropRx certified EHR solution. This is the companion document to our CY 2024 real world test plan that described our approach for conducting real world testing in CY 2024 and the testing measures we employed.

Our findings show that EHR is working in our production as it was certified. For our CY 2024 Real World Testing Measure, we have recorded our results and findings. We did not discover any non-conformities or errors from our testing.

Our signed attestation of compliance with the real world testing requirements is on the following page.

Developer Attestation

This Real World Testing report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Signature:

A handwritten signature in black ink, appearing to be "H. M.", written over a horizontal line.

DATE

2/1/2025

Executive Summary	1
Developer Attestation.....	2
General Information	4
Timeline and Milestones for Real World Testing CY 2024.....	5
Standards Version Advancement Process (SVAP) Updates	6
RWT Measure #1. Number of NewRx Prescription Messages Successfully Sent	7

General Information

Plan Report ID Number: NewCropRx-RWT-2024

Developer Name: NewCropRx

Product Name(s): NewCropRx

Version Numbers: 2.01

Certified Health IT Criteria: 315(b)(3)

Product List (CHPL) ID(s) and Link(s):

- 15.04.04.3135.NCRX.02.00.0.221223
- <https://chpl.healthit.gov/#/listing/11122>

Developer Real World Testing Page URL: <https://info.therapybrands.com/newcrop-real-world-testing>

Timeline and Milestones for Real World Testing CY 2024

- Milestone 1Q-2024: Health IT system is fully enabled for use in real world testing.
 - STATUS: MET
- Milestone 3Q 2024. Begin making plans to collect data for RWT measures. If necessary, engage clients to ask for their support and participation in real world testing.
 - STATUS: MET
- Milestone 4Q-2024. During the last quarter of the year, the CY 2024 real world test plan will be completed according to ONC and ONC-ACB requirements and expectations. Test plan will be prepared for submission.
 - STATUS: MET

Standards Version Advancement Process (SVAP) Updates

For CY 2024 RWT testing, we did not do any SVAP updates but used the current standards required in the certification criteria.

RWT Measure #1. Number of NewRx Prescription Messages Successfully Sent

Associated Criteria: 315(b)(3)

Measurement Description

This measure tracks and counts how many NewRx electronic prescriptions created and successfully sent from our Health IT Module to a pharmacy destination over the course of a given interval.

Care Settings

NewCropRx supports a wide range of healthcare practices in the ambulatory space. For this year test, we had many behavioral health practices, county health organizations, and family practices selected for our test group.

Testing Results

Testing Metric/Measurement: Number of NewRx Prescription Messages Sent

EHR Partners Selected: 5

Practices Selected: 344

Reporting Period: Jan 1-Dec 31, 2024

Total NewRx Messages Successfully Sent: 1,888,514

Success Rate: 99.19%

Analysis and Key Findings

NewCropRx is used in connection with other EHRs to provide the ePrescribing features for their practice customers. For our testing, we selected five of our EHR partners to use in our testing sample. These EHR developers collectively had 344 different practices using ePrescribing through NewCropRx. For the year, these 344 practices successfully sent over 1.8 million NewRx messages with a pharmacy delivery success rate of over 99%.

Our results show strong use of our solution across a range of providers and care settings, from behavioral health to family practice to county health organizations.

Non-Conformities or Errors Discovered

During our testing, we did not discover any certification errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.